Recombinant rotaviruses and methods and systems for producing the same

EP4598570A2Pending Publication Date: 2025-08-13THE TRUSTEES OF INDIANA UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2023875895
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-29
Filing Date
2023-10-09
Publication Date
2025-08-13

AI Technical Summary

Technical Problem

Current rotavirus vaccines, such as Rotarix, have limitations in providing broad protection against multiple pathogens, particularly norovirus and SARS-CoV-2, and there is a need for novel recombinant rotaviruses that can serve as effective vaccines for children.

Method used

Development of a reverse genetics system for the human G1P[8] rotavirus strain RIX4414, allowing the expression of heterologous proteins from norovirus and SARS-CoV-2 by inserting sequences into RIX4414 segment 7, enabling the generation of recombinant rotaviruses that can encode multiple antigens and serve as a vaccine vector.

Benefits of technology

The system enables the production of recombinant rotaviruses capable of expressing norovirus and SARS-CoV-2 antigens, potentially leading to combined vaccination against rotavirus and norovirus, enhancing immunological protection against severe gastroenteritis in children.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1.1
    Figure 1.1
Patent Text Reader

Abstract

Disclosed are novel recombinant rotaviruses and methods of making the same, systems for generating the same, as well as methods of using the same to elicit an immune response in a subject or to vaccinate a subject against rotavirus infection and infection.
Need to check novelty before this filing date? Find Prior Art